| Market Capitalization (Millions $) |
1,762 |
| Shares
Outstanding (Millions) |
85 |
| Employees |
159 |
| Revenues (TTM) (Millions $) |
394 |
| Net Income (TTM) (Millions $) |
504 |
| Cash Flow (TTM) (Millions $) |
284 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Innoviva Inc (formerly known as Theravance Inc) is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies for respiratory diseases. The company was founded in 1996 and is headquartered in South San Francisco, California, with additional offices in various countries around the world.
Innoviva's mission is to improve the lives of patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, among others. The company's focus is on developing new and more effective ways of delivering drugs to the lungs, which can be a challenging task due to the complex structure of this organ.
One of the main products developed by Innoviva is the Ellipta inhaler, which is used for the treatment of COPD and asthma. This inhaler uses a proprietary dry powder delivery technology that makes it easier for patients to inhale the medication and ensures that the drug reaches the lungs in sufficient quantities to achieve therapeutic effect.
In addition to the Ellipta inhaler, Innoviva has a range of other respiratory drugs in its pipeline, including several in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim. These drugs are in various stages of clinical development and are aimed at addressing the unmet needs of patients suffering from a range of respiratory diseases.
Apart from its focus on respiratory disease therapies, Innoviva also has a strong commitment to environmental sustainability. The company places great emphasis on reducing its carbon footprint and has adopted various measures to achieve this goal, such as minimizing waste generation, reducing energy consumption, and promoting the use of renewable energy sources.
Overall, Innoviva Inc has established a strong reputation for its innovative respiratory disease therapies and its commitment to environmental sustainability. The company's continued focus on R&D, collaboration with major pharmaceutical companies, and its dedication to improving patient outcomes makes it a key player in the biopharmaceutical industry.
Company Address: 1350 Old Bayshore Highway Suite 400 Burlingame 94010 CA
Company Phone Number: 238-9600 Stock Exchange / Ticker: NASDAQ INVA
|
60.73 %